Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The claims accurately describe the labeled use for temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold, and several listed adverse reactions. However, many claims about mechanisms, interactions, patient risk groups, and alternative treatments are not supported by the supplied label sections. The claims also omit important details of the supplied contraindications.
Category Scores
Accurate Statements
The combination is used for cough symptoms and temporary relief of upper respiratory symptoms associated with allergy or the common cold.
Indications and Usage states that promethazine with codeine syrup is indicated for temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold.
Promethazine can have sedating effects.
Adverse Reactions identifies drowsiness as promethazine's most prominent CNS effect and also lists sedation and somnolence.
Promethazine–codeine products can cause drowsiness, dizziness, constipation, nausea, and respiratory depression.
Adverse Reactions lists these effects for promethazine and/or codeine, including potentially fatal respiratory depression for promethazine.
The combination contains promethazine and codeine.
Description specifies promethazine hydrochloride and codeine phosphate in the syrup.
Unsupported Statements
The product name “Quagen promethazine codeine” identifies this specific product.
The supplied Description identifies the ingredients but does not mention the Quagen brand.
The combination can help with associated nausea.
The supplied label lists nausea as an adverse reaction, not as an indication or treatment benefit.
The exact indication, dosing, and strengths depend on the specific product label and regulatory approval in the relevant market.
The supplied sections do not discuss differences among products, markets, or regulatory approvals.
Promethazine is an antihistamine and can reduce allergy-related symptoms as an individual ingredient.
The supplied sections do not identify promethazine as an antihistamine or attribute the labeled relief specifically to promethazine.
Codeine is an opioid cough suppressant that works in the brain and spinal cord to reduce the cough reflex.
The supplied sections do not classify codeine this way or describe its mechanism of action.
The product impairs alertness.
The supplied Adverse Reactions section lists drowsiness, sedation, dizziness, and visual effects but does not expressly state that alertness is impaired.
Respiratory-depression risk is especially increased at higher doses or when combined with other depressants.
The supplied sections list respiratory depression but do not state these dose-related or concomitant-depressant qualifications.
The listed risks are heightened when codeine is involved.
The supplied sections do not make this comparative risk statement.
Alcohol, benzodiazepines, other opioids, sleep medicines, muscle relaxants, or other CNS-depressant substances increase sedation, respiratory-depression, or overdose risk when taken with codeine.
The supplied sections contain no drug-interaction information supporting these claims.
People with sleep apnea or COPD, or people with a history of substance use disorder, are high-risk for this combination.
The supplied sections do not identify these groups as high-risk. They do contraindicate use of antihistamines and codeine to treat lower respiratory tract symptoms, including asthma.
Opioid exposure during pregnancy or breastfeeding requires careful evaluation.
The supplied sections do not address pregnancy or breastfeeding.
Contraindications vary by jurisdiction and product label.
The supplied sections do not discuss jurisdictional or product-to-product variation.
Non-opioid cough suppressants, treating the underlying cause, antihistamines, inhalers, or codeine-free formulations may be alternatives.
The supplied sections do not recommend or discuss these alternatives.
Contradictions
Important Omissions
The supplied label contraindicates this combination in pediatric patients younger than 6 years because of potentially fatal respiratory depression.
Importance:
High
The supplied label also lists contraindications for codeine hypersensitivity; promethazine hypersensitivity or idiosyncratic reaction to promethazine or other phenothiazines; comatose states; and treatment of lower respiratory tract symptoms, including asthma.
Importance:
High
The labeled indication is specifically temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold; it does not establish nausea relief or general allergy-symptom relief.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The claims include unsupported risk and interaction details and do not clearly state the supplied label's pediatric and other contraindications. The supplied label does identify respiratory depression, including potentially fatal effects, as an adverse reaction.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Numerous interaction, mechanism, population-risk, and alternative-treatment claims are not supported by the supplied label sections, and key listed contraindications are omitted.
Suggested Improvement
Limit claims to the supplied label: state the temporary relief indication, accurately describe listed adverse reactions, and include the specified contraindications. Do not present interaction claims or alternatives as label-supported when they are absent from the supplied sections.